{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:46:28Z","timestamp":1779241588191,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/bmt.2017.201","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T15:09:19Z","timestamp":1506956959000},"page":"1609-1615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Donor T-cell responses and disease progression patterns of multiple myeloma"],"prefix":"10.1038","volume":"52","author":[{"given":"M","family":"Eefting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L C","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P A","family":"Von dem Borne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J M","family":"Halkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E W A","family":"Marijt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Putter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H F","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,2]]},"reference":[{"key":"BFbmt2017201_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","volume":"2013","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, San Miguel JF . How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program 2013; 2013: 488\u2013495.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2017201_CR2","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1182\/blood-2012-04-420802","volume":"119","author":"P Moreau","year":"2012","unstructured":"Moreau P . Death of frontline allo-SCT in myeloma. Blood 2012; 119: 6178\u20136179.","journal-title":"Blood"},{"key":"BFbmt2017201_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/bmt.2015.319","volume":"51","author":"I Ahmad","year":"2016","unstructured":"Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G et al. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation. Bone Marrow Transplant 2016; 51: 529\u2013535.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR4","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","volume":"119","author":"HM Lokhorst","year":"2012","unstructured":"Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219\u20136225 quiz 399.","journal-title":"Blood"},{"key":"BFbmt2017201_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/bmt.2015.325","volume":"51","author":"B Dhakal","year":"2016","unstructured":"Dhakal B, Vesole DH, Hari PN . Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant 2016; 51: 492\u2013500.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: 1195\u20131203.","journal-title":"Lancet Oncol"},{"key":"BFbmt2017201_CR7","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","volume":"121","author":"G Gahrton","year":"2013","unstructured":"Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H et al. Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055\u20135063.","journal-title":"Blood"},{"key":"BFbmt2017201_CR8","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1182\/blood-2008-07-168823","volume":"112","author":"P Moreau","year":"2008","unstructured":"Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008; 112: 3914\u20133915.","journal-title":"Blood"},{"key":"BFbmt2017201_CR9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016; 128: 1688\u20131700.","journal-title":"Blood"},{"key":"BFbmt2017201_CR10","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/blood-2006-08-043935","volume":"109","author":"CA van Bergen","year":"2007","unstructured":"van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood 2007; 109: 4089\u20134096.","journal-title":"Blood"},{"key":"BFbmt2017201_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","volume":"103","author":"WA Bethge","year":"2004","unstructured":"Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790\u2013795.","journal-title":"Blood"},{"key":"BFbmt2017201_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1083-8791(00)70014-0","volume":"6","author":"E Orsini","year":"2000","unstructured":"Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 375\u2013386.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1191\/0962280202sm277ra","volume":"11","author":"JP Klein","year":"2002","unstructured":"Klein JP, Shu Y . Multi-state models for bone marrow transplantation studies. Stat Methods Med Res 2002; 11: 117\u2013139.","journal-title":"Stat Methods Med Res"},{"key":"BFbmt2017201_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/bmt.2013.111","volume":"49","author":"M Eefting","year":"2014","unstructured":"Eefting M, Halkes CJ, de Wreede LC, van Pelt CM, Kersting S, Marijt EW et al. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant 2014; 49: 287\u2013291.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1046\/j.1365-2141.2000.01982.x","volume":"109","author":"JP Klein","year":"2000","unstructured":"Klein JP, Keiding N, Shu Y, Szydlo RM, Goldman JM . Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve. Br J Haematol 2000; 109: 148\u2013152.","journal-title":"Br J Haematol"},{"key":"BFbmt2017201_CR16","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9","volume":"19","author":"JP Klein","year":"2000","unstructured":"Klein JP, Szydlo RM, Craddock C, Goldman JM . Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. Stat Med 2000; 19: 3005\u20133016.","journal-title":"Stat Med"},{"key":"BFbmt2017201_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","volume":"99","author":"LC de Wreede","year":"2010","unstructured":"de Wreede LC, Fiocco M, Putter H . The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 2010; 99: 261\u2013274.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFbmt2017201_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC de Wreede","year":"2011","unstructured":"de Wreede LC, Fiocco M, Putter H . mstate: an R package for the analysis of competing risks and multi-state models. J Stat Softw 2011; 38: 1\u201330.","journal-title":"J Stat Softw"},{"key":"BFbmt2017201_CR19","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.4049\/jimmunol.1300651","volume":"191","author":"CC Brinkman","year":"2013","unstructured":"Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH . Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells. J Immunol 2013; 191: 2412\u20132425.","journal-title":"J Immunol"},{"key":"BFbmt2017201_CR20","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2012-12-470872","volume":"122","author":"S Stevanovic","year":"2013","unstructured":"Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB et al. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood 2013; 122: 1963\u20131973.","journal-title":"Blood"},{"key":"BFbmt2017201_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbmt.2012.12.014","volume":"19","author":"R van der Voort","year":"2013","unstructured":"van der Voort R, Volman TJ, Verweij V, Linssen PC, Maas F, Hebeda KM et al. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 378\u2013386.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1365-2141.2003.04670.x","volume":"123","author":"T Luft","year":"2003","unstructured":"Luft T, Moos M, Goldschmidt H, Ho AD, Gorner M . Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646\u2013653.","journal-title":"Br J Haematol"},{"key":"BFbmt2017201_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","volume":"41","author":"MC Minnema","year":"2008","unstructured":"Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant 2008; 41: 779\u2013784.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","volume":"9","author":"KS Peggs","year":"2003","unstructured":"Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257\u2013265.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14653240701732771","volume":"10","author":"N Novitzky","year":"2008","unstructured":"Novitzky N, Thomas V, du Toit C . Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome. Cytotherapy 2008; 10: 45\u201353.","journal-title":"Cytotherapy"},{"key":"BFbmt2017201_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016; 374: 43\u201353.","journal-title":"N Engl J Med"},{"key":"BFbmt2017201_CR27","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/01.cco.0000357472.76337.0e","volume":"21","author":"PA von dem Borne","year":"2009","unstructured":"von dem Borne PA, Starrenburg CW, Halkes SJ, Marijt WA, Fibbe WE, Falkenburg JH et al. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag'). Curr Opin Oncol 2009; 21: S27\u2013S29.","journal-title":"Curr Opin Oncol"},{"key":"BFbmt2017201_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1046\/j.1365-2141.2003.04612.x","volume":"123","author":"S D'Sa","year":"2003","unstructured":"D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123: 309\u2013322.","journal-title":"Br J Haematol"},{"key":"BFbmt2017201_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood.V98.4.934","volume":"98","author":"E Alyea","year":"2001","unstructured":"Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D et al. T-cell\u2014depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98: 934\u2013939.","journal-title":"Blood"},{"key":"BFbmt2017201_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1365-2141.2001.02599.x","volume":"112","author":"N Kroger","year":"2001","unstructured":"Kroger N, Kruger W, Renges H, Zabelina T, Stute N, Jung R et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: 421\u2013423.","journal-title":"Br J Haematol"},{"key":"BFbmt2017201_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbmt.2009.10.006","volume":"16","author":"H Levenga","year":"2010","unstructured":"Levenga H, Schaap N, Maas F, Esendam B, Fredrix H, Greupink-Draaisma A et al. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 320\u2013332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","volume":"37","author":"N Kroger","year":"2009","unstructured":"Kroger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37: 791\u2013798.","journal-title":"Exp Hematol"},{"key":"BFbmt2017201_CR33","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV . Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book 2016; 35: e418\u2013e423.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"BFbmt2017201_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","volume":"1364","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR . Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci 2016; 1364: 32\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"BFbmt2017201_CR35","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","volume":"104","author":"N Kroger","year":"2004","unstructured":"Kroger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: 3361\u20133363.","journal-title":"Blood"},{"key":"BFbmt2017201_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.exphem.2012.02.009","volume":"40","author":"J El-Cheikh","year":"2012","unstructured":"El-Cheikh J, Crocchiolo R, Furst S, Ladaique P, Castagna L, Faucher C et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 2012; 40: 521\u2013527.","journal-title":"Exp Hematol"},{"key":"BFbmt2017201_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/bmt.2010.56","volume":"46","author":"IA Hoevenaren","year":"2011","unstructured":"Hoevenaren IA, van Vulpen LF, Levenga H, Minnema MC, Raymakers R . Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions. Bone Marrow Transplant 2011; 46: 319\u2013321.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.bmt.1701960","volume":"24","author":"D Rondelli","year":"1999","unstructured":"Rondelli D, Bandini G, Cavo M, Re F, Motta M, Senese B et al. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. Bone Marrow Transplant 1999; 24: 685\u2013687.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR39","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.molonc.2015.10.014","volume":"9","author":"JH Falkenburg","year":"2015","unstructured":"Falkenburg JH, Jedema I . Allo-reactive T cells for the treatment of hematological malignancies. Mol Oncol 2015; 9: 1894\u20131903.","journal-title":"Mol Oncol"},{"key":"BFbmt2017201_CR40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.it.2005.04.011","volume":"26","author":"F Di Rosa","year":"2005","unstructured":"Di Rosa F, Pabst R . The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005; 26: 360\u2013366.","journal-title":"Trends Immunol"},{"key":"BFbmt2017201_CR41","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","volume":"22","author":"L Rasche","year":"2016","unstructured":"Rasche L, Rollig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transplant 2016; 22: 1988\u20131996.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/sj.bmt.1705393","volume":"37","author":"NW van de Donk","year":"2006","unstructured":"van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006; 37: 1135\u20131141.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017201_CR43","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/sj.leu.2403432","volume":"18","author":"K Peggs","year":"2004","unstructured":"Peggs K, Mackinnon S . Graft-versus-myeloma: are durable responses a clinical reality following donor lymphocyte infusion? Leukemia 2004; 18: 1541\u20131542.","journal-title":"Leukemia"},{"key":"BFbmt2017201_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","volume":"120","author":"IM Ghobrial","year":"2012","unstructured":"Ghobrial IM . Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012; 120: 20\u201330.","journal-title":"Blood"},{"key":"BFbmt2017201_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","volume":"10","author":"EF Posthuma","year":"2004","unstructured":"Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10: 204\u2013212.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.bbmt.2012.06.017","volume":"18","author":"B van der Zouwen","year":"2012","unstructured":"van der Zouwen B, Kruisselbrink AB, Jordanova ES, Rutten CE, von dem Borne PA, Falkenburg JH et al. Alloreactive effector T cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with nonhematopoietic tissues to induce GVHD reactivity. Biol Blood Marrow Transplant 2012; 18: 1353\u20131367.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017201_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/jjco\/hyp104","volume":"39","author":"K Ishiyama","year":"2009","unstructured":"Ishiyama K, Takami A, Suzuki S, Konaka H, Namiki M, Ooi A et al. Relationship between tumor-infiltrating T lymphocytes and clinical response after reduced-intensity allogeneic hematopoietic stem cell transplantation for advanced renal cell carcinoma: a single center prospective study. Jpn J Clin Oncol 2009; 39: 807\u2013812.","journal-title":"Jpn J Clin Oncol"},{"key":"BFbmt2017201_CR48","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","volume":"190","author":"TJ Kearl","year":"2013","unstructured":"Kearl TJ, Jing W, Gershan JA, Johnson BD . Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620\u20135628.","journal-title":"J Immunol"},{"key":"BFbmt2017201_CR49","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","volume":"125","author":"P Armand","year":"2015","unstructured":"Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393\u20133400.","journal-title":"Blood"},{"key":"BFbmt2017201_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375: 143\u2013153.","journal-title":"N Engl J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2017201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017201","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:20:30Z","timestamp":1648063230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2017201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,2]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFbmt2017201"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.201","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,2]]},"assertion":[{"value":"19 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}